Home › Companies › CG ONCOLOGY INC. › 2024-2025
At CG ONCOLOGY INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 60 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 683 separate fund positions. On the most widely held item on that ballot — To elect the Board's three nominees for Class I director named as nominees to hold office until… — CG ONCOLOGY INC.'s filing reports the nominee as elected, with 94% support of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CG ONCOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CG ONCOLOGY INC.’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 5, 2025: 4 items on CG ONCOLOGY INC.’s Form 8-K, filed June 6, 2025: 3 elected · 1 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore CG ONCOLOGY INC. in the interactive database Compare manager voting policies
These tallies are CG ONCOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Arthur Kuan | 57,636,262 | -- | -- | 3,625,893 | 8,448,008 | 94% | Elected | — |
| Elect Director: James J. Mulé | 34,062,064 | -- | -- | 27,200,091 | 8,448,008 | 56% | Elected | — |
| Elect Director: Leonard Post | 52,459,292 | -- | -- | 8,802,863 | 8,448,008 | 86% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 69,688,802 | 7,027 | 14,335 | -- | -- | 99.9% | Approved | — |
Source: CG ONCOLOGY INC., Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.
Each item below shows how the 60 asset managers that disclosed a CG ONCOLOGY INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's three nominees for Class I director named as nominees to hold office until the 2028 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Arthur Kuan
CG ONCOLOGY INC.’s own tally for this item (“Elect Director: Arthur Kuan”): 57,636,262 for, 3,625,893 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or re…”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 14,800,442 for, 760,044 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,776,073 | 0 | 0 | 0 | For |
| Fidelity | 3,000,379 | 0 | 0 | 0 | For |
| BlackRock | 1,816,096 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 854,304 | 0 | 0 | 0 | For |
| AllianceBernstein | 633,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 500,153 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 439,572 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 385,020 | 0 | 0 | 0 | For |
| Equitable | 283,996 | 0 | 0 | 0 | For |
| MFS | 226,783 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 171,960 | 0 | 0 | 0 | For |
| TIAA | 162,983 | 0 | 0 | 0 | For |
| Principal | 126,448 | 0 | 0 | 124 | For |
| State Street | 125,608 | 0 | 0 | 1 | For |
| QUANTITATIVE MASTER SERIES LLC | 92,084 | 0 | 0 | 0 | For |
| Hartford | 0 | 0 | 0 | 89,919 | Withhold |
| Goldman Sachs | 88,176 | 0 | 0 | 0 | For |
| Northwestern Mutual | 0 | 0 | 0 | 75,561 | Withhold |
| Prudential/PGIM | 62,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 58,669 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 0 | 0 | 0 | 52,561 | Withhold |
| Pacific Life | 52,360 | 0 | 0 | 0 | For |
| Franklin Templeton | 42,400 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 34,953 | 0 | 0 | 0 | For |
| Brighthouse | 19,114 | 0 | 0 | 13,503 | Mixed |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
56% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's three nominees for Class I director named as nominees to hold office until the 2028 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: James J. Mule
CG ONCOLOGY INC.’s own tally for this item (“Elect Director: James J. Mulé”): 34,062,064 for, 27,200,091 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or re…”
Support: 56% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 1,046,214 for, 14,514,272 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 5,776,073 | Withhold |
| Fidelity | 0 | 0 | 0 | 3,000,379 | Withhold |
| BlackRock | 0 | 0 | 0 | 1,816,096 | Withhold |
| FRANKLIN STRATEGIC SERIES | 854,304 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 633,541 | Withhold |
| T. Rowe Price | 0 | 0 | 0 | 500,153 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 439,572 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 385,020 | Withhold |
| Equitable | 0 | 0 | 0 | 283,996 | Withhold |
| MFS | 0 | 0 | 0 | 226,783 | Withhold |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 171,960 | Withhold |
| TIAA | 0 | 0 | 0 | 162,983 | Withhold |
| Principal | 0 | 0 | 0 | 126,572 | Withhold |
| State Street | 155 | 0 | 0 | 125,454 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 92,084 | Withhold |
| Hartford | 0 | 0 | 0 | 89,919 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 88,176 | Withhold |
| Northwestern Mutual | 0 | 0 | 0 | 75,561 | Withhold |
| Prudential/PGIM | 62,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 58,669 | Withhold |
| MERIDIAN FUND INC | 0 | 0 | 0 | 52,561 | Withhold |
| Pacific Life | 0 | 0 | 0 | 52,360 | Withhold |
| Franklin Templeton | 42,400 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 34,953 | Withhold |
| Brighthouse | 0 | 0 | 0 | 32,617 | Withhold |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: To elect the Board's three nominees for Class I director named as nominees to hold office until the 2028 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Leonard Post
CG ONCOLOGY INC.’s own tally for this item (“Elect Director: Leonard Post”): 52,459,292 for, 8,802,863 withheld, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or re…”
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 14,074,097 for, 1,486,389 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,776,073 | 0 | 0 | 0 | For |
| Fidelity | 3,000,379 | 0 | 0 | 0 | For |
| BlackRock | 1,816,096 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 854,304 | 0 | 0 | 0 | For |
| AllianceBernstein | 633,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 500,153 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 439,572 | Withhold |
| AB DISCOVERY GROWTH FUND, INC. | 385,020 | 0 | 0 | 0 | For |
| Equitable | 283,996 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 226,783 | Withhold |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 171,960 | Withhold |
| TIAA | 162,983 | 0 | 0 | 0 | For |
| Principal | 126,448 | 0 | 0 | 124 | For |
| State Street | 125,463 | 0 | 0 | 146 | For |
| QUANTITATIVE MASTER SERIES LLC | 92,084 | 0 | 0 | 0 | For |
| Hartford | 0 | 0 | 0 | 89,919 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 88,176 | Withhold |
| Northwestern Mutual | 0 | 0 | 0 | 75,561 | Withhold |
| Prudential/PGIM | 62,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 40,000 | 0 | 0 | 18,669 | Mixed |
| MERIDIAN FUND INC | 0 | 0 | 0 | 52,561 | Withhold |
| Pacific Life | 21,035 | 0 | 0 | 31,325 | Mixed |
| Franklin Templeton | 42,400 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 34,953 | Withhold |
| Brighthouse | 0 | 0 | 0 | 32,617 | Withhold |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE BOARD OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
CG ONCOLOGY INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 69,688,802 for, 7,027 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 15,546,983 for, 13,503 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,776,073 | 0 | 0 | 0 | For |
| Fidelity | 3,000,379 | 0 | 0 | 0 | For |
| BlackRock | 1,816,096 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 854,304 | 0 | 0 | 0 | For |
| AllianceBernstein | 633,541 | 0 | 0 | 0 | For |
| T. Rowe Price | 500,153 | 0 | 0 | 0 | For |
| Charles Schwab | 439,572 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 385,020 | 0 | 0 | 0 | For |
| Equitable | 283,996 | 0 | 0 | 0 | For |
| MFS | 226,783 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 171,960 | 0 | 0 | 0 | For |
| TIAA | 162,983 | 0 | 0 | 0 | For |
| Principal | 126,572 | 0 | 0 | 0 | For |
| State Street | 125,609 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 92,084 | 0 | 0 | 0 | For |
| Hartford | 89,919 | 0 | 0 | 0 | For |
| Goldman Sachs | 88,176 | 0 | 0 | 0 | For |
| Northwestern Mutual | 75,561 | 0 | 0 | 0 | For |
| Prudential/PGIM | 62,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 58,669 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 52,561 | 0 | 0 | 0 | For |
| Pacific Life | 52,360 | 0 | 0 | 0 | For |
| Franklin Templeton | 42,400 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 34,953 | 0 | 0 | 0 | For |
| Brighthouse | 19,114 | 0 | 13,503 | 0 | Mixed |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 76,221,289 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.58% |
| 2 | Fidelity | 3.94% |
| 3 | BlackRock | 2.38% |
| 4 | FRANKLIN STRATEGIC SERIES | 1.12% |
| 5 | AllianceBernstein | 0.83% |
| 6 | T. Rowe Price | 0.66% |
| 7 | Charles Schwab | 0.58% |
| 8 | AB DISCOVERY GROWTH FUND, INC. | 0.51% |
| 9 | Equitable | 0.37% |
| 10 | MFS | 0.30% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| RTW Investments, LP | 9.16% | 13G |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 8.36% | DEF14A |
| Xiangmin Cui | 8.36% | 13G |
| Vanguard Group | 7.66% | 13F |
| Entities affiliated with Longitude Venture Partners | 6.12% | DEF14A |
| Patrick G. Enright | 6.12% | 13D |
| BlackRock | 5.71% | 13F |
| SONG, Hong Fang | 5.53% | 13G |
| Simone Song | 5.19% | DEF14A |
| FMR LLC | 5.06% | 13G |
Percentages above are of 76,221,289 shares outstanding, as reported by CG ONCOLOGY INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CG ONCOLOGY INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CG ONCOLOGY INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “CG ONCOLOGY (CGON) 2025 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/cg-oncology-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.